Anti-YARS2/TyRS antibody (ab228957)
Key features and details
- Rabbit polyclonal to YARS2/TyRS
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-YARS2/TyRS antibody -
Description
Rabbit polyclonal to YARS2/TyRS -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment within Human YARS2/TyRS (internal sequence). The exact sequence is proprietary.
Database link: Q9Y2Z4 -
Positive control
- IHC-P: Human colon carcinoma tissue. WB: NTERA-2 cl.D1 [NT2/D1] whole cell lysate.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 1.21% Tris, 0.75% Glycine, 20% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab228957 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/500 - 1/3000. Predicted molecular weight: 53 kDa.
|
|
IHC-P |
1/100 - 1/1000.
|
Notes |
---|
WB
1/500 - 1/3000. Predicted molecular weight: 53 kDa. |
IHC-P
1/100 - 1/1000. |
Target
-
Function
Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr). -
Involvement in disease
Defects in YARS2 are the cause of myopathy with lactic acidosis and sideroblastic anemia type 2 (MLASA2) [MIM:613561]. MLASA2 is a rare oxidative phosphorylation disorder specific to skeletal muscle and bone marrow. Affected individuals manifest sideroblastic anemia, progressive lethargy, muscle weakness, and exercise intolerance associated with persistent lactic acidemia. -
Sequence similarities
Belongs to the class-I aminoacyl-tRNA synthetase family. -
Cellular localization
Mitochondrion matrix. - Information by UniProt
-
Database links
- Entrez Gene: 51067 Human
- Omim: 610957 Human
- SwissProt: Q9Y2Z4 Human
- Unigene: 505231 Human
- Unigene: 706015 Human
-
Alternative names
- CGI 04 antibody
- FLJ13995 antibody
- mitochondrial antibody
see all
Images
-
Paraffin-embedded human colon carcinoma tissue stained for YARS2/TyrRS using ab228957 at 1/250 dilution in immunohistochemical analysis.
-
Anti-YARS2/TyRS antibody (ab228957) at 1/1000 dilution + NTERA-2 cl.D1 [NT2/D1] (human malignant pluripotent embryonic carcinoma cell line) whole cell lysate at 30 µg
Predicted band size: 53 kDa10% SDS PAGE gel.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab228957 has been referenced in 2 publications.
- Fang Q et al. Targeting mitochondrial tyrosyl-tRNA synthetase YARS2 suppresses colorectal cancer progression. Cancer Biol Ther 23:1-8 (2022). PubMed: 36154909
- Chen D et al. Deletion of Gtpbp3 in zebrafish revealed the hypertrophic cardiomyopathy manifested by aberrant mitochondrial tRNA metabolism. Nucleic Acids Res 47:5341-5355 (2019). PubMed: 30916346